Claire Kuo

Claire Kuo

Auto-generated profile, based on publicly available information

Claire Kuo

Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, 6720A Rockledge Drive, Suite 300, Bethesda, MD 20817, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Pathology
Verified
Journal Article
Open access
STShyh-Han Tan
Shyh-Han Tan
DYDenise Young
Denise Young
YCYongmei Chen
Yongmei Chen
HKHuai-Ching Kuo
Huai-Ching Kuo
ASAlagarsamy Srinivasan
Alagarsamy Srinivasan
ISIsabell A. Sesterhenn
Isabell A. Sesterhenn
ANXA2 (Annexin A2 or Annexin II) is a calcium dependent phospholipid binding protein with diverse cellular functions. While ANXA2 is either absent or expressed focally in the prostate epithelium of well and moderately differentiated tumours, it is highly expressed in a subset of poorly differentiated tumours. Here we examined the association between ANXA2 expression and tumour progression, with consideration of ERG expression status and patient race (Caucasian American and African American).

12 December 2019 in Cancers
Verified
Journal Article
Open access
PDF file
Shashwat SharadShashwat Sharad
Shashwat Sharad
ZSZsófia M. Sztupinszki
Zsófia M. Sztupinszki
YCYongmei Chen
Yongmei Chen
CKClaire Kuo
Claire Kuo
LRLakshmi Ravindranath
Lakshmi Ravindranath
HLHua Li
Hua Li
Dysfunctions of androgen/TGF-β signaling play important roles in prostate tumorigenesis. Prostate Transmembrane Protein Androgen Induced 1 (PMEPA1) inhibits androgen and TGF-β signaling via a negative feedback loop. The loss of PMEPA1 confers resistance to androgen signaling inhibitors and promotes bone metastasis. Conflicting reports on the expression and biological functions of PMEPA1 in prostate and other cancers propelled us to investigate isoform specific functions in prostate cancer (PCa). One hundred and twenty laser capture micro-dissection matched normal prostate and prostate tumor tissues were analyzed for correlations between quantitative expression of PMEPA1 isoforms and clinical outcomes with Q-RT-PCR, and further validated with a The Cancer Genome Atlas (TCGA) RNA-Seq dataset of 499 PCa. Cell proliferation was assessed with cell counting, plating efficiency and soft agar assay in androgen responsive LNCaP and TGF-β responsive PC3 cells. TGF-β signaling was measured by SMAD dual-luciferase reporter assay. Higher PMEPA1-a mRNA levels indicated biochemical recurrence (p = 0.0183) and lower PMEPA1-b expression associated with metastasis (p = 0.0173). Further, lower PMEPA1-b and a higher ratio of PMEPA1-a vs. -b were correlated to higher Gleason scores and lower progression free survival rate (p < 0.01). TGF-β-responsive PMEPA1-a promoted PCa cell growth, and androgen-responsive PMEPA1-b inhibited cancer cell proliferation. PMEPA1 isoforms -a and -b were shown to be promising candidate biomarkers indicating PCa aggressiveness including earlier biochemical relapse and lower disease specific life expectancy via interrupting androgen/TGF-β signaling.

17 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
YGYuqian Gao
Yuqian Gao
YiTing WangYiTing Wang
YiTing Wang
YCYongmei Chen
Yongmei Chen
HWHui Wang
Hui Wang
DYDenise Young
Denise Young
Tao LiuTao Liu
Tao Liu
Although ~40% of screen-detected prostate cancers (PCa) are indolent, advanced-stage PCa is a lethal disease with 5-year survival rates around 29%. Identification of biomarkers for early detection of aggressive disease is a key challenge. Starting with 52 candidate biomarkers, selected from existing PCa genomics datasets and known PCa driver genes, we used targeted mass spectrometry to quantify proteins that significantly differed in primary tumors from PCa patients treated with radical prostatectomy (RP) across three study outcomes: (i) metastasis ≥1-year post-RP, (ii) biochemical recurrence ≥1-year post-RP, and (iii) no progression after ≥10 years post-RP. Sixteen proteins that differed significantly in an initial set of 105 samples were evaluated in the entire cohort (n = 338). A five-protein classifier which combined FOLH1, KLK3, TGFB1, SPARC, and CAMKK2 with existing clinical and pathological standard of care variables demonstrated significant improvement in predicting distant metastasis, achieving an area under the receiver-operating characteristic curve of 0.92 (0.86, 0.99, p = 0.001) and a negative predictive value of 92% in the training/testing analysis. This classifier has the potential to stratify patients based on risk of aggressive, metastatic PCa that will require early intervention compared to low risk patients who could be managed through active surveillance.

1 October 2020 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
FCFernando Caumont
Fernando Caumont
GCGalen Conti
Galen Conti
LHLauren Hurwitz
Lauren Hurwitz
CKClaire Kuo
Claire Kuo
KLKatherine E. Levie
Katherine E. Levie
CPChristopher R. Porter
Christopher R. Porter


4 March 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Shashwat SharadShashwat Sharad
Shashwat Sharad
ZSZsófia M. Sztupinszki
Zsófia M. Sztupinszki
YCYongmei Chen
Yongmei Chen
CKClaire Kuo
Claire Kuo
LRLakshmi Ravindranath
Lakshmi Ravindranath
HLHua Li
Hua Li
The journal retracts the article titled “Analysis of PMEPA1 Isoforms (a and b) as Selective Inhibitors of Androgen and TGF-β Signaling Reveals Distinct Biological and Prognostic Features in Prostate Cancer”